Tröbs M, Achenbach S, Nef HM, et al. - Researchers looked for potential disparities in 2-year results between patients who received coronary revascularization using bioresorbable vascular scafffolds (BVS) in stable coronary artery disease (CAD) and acute coronary syndromes (ACS). Using a German-Austrian ABSORB RegIstRy, which represents a prospective all-comer multicenter observational study of consecutive patients who were considered for coronary revascularization with BVS, experts compared 1,499 patients with stable CAD vs 1,594 patients suffering from ACS. Major adverse cardiac events (MACE), target lesion failure (TLF), and scaffold thrombosis, all were set as endpoints. In ACS and in stable CAD, 2-year MACE rates were 11.6% and 11.4%, respectively, and TLF occurred in 7.0% vs 7.4% and target vessel revascularization in 8.8 vs 10.2% (n.s. for all). Findings revealed no significant difference in real-world 2-year event rates, post-coronary revascularization with BVS, between patients with ACS vs stable CAD.